title: Impact of body mass index on treatment efficacy of mirabegron for overactive bladder in females.
abstract: OBJECTIVE
  Conclusive data comparing treatment efficacy of OAB pharmacotherapy in normal weight versus obese patients are not available. Obesity represents a risk factor for OAB/LUTS. We hypothesized that the effect of treatment with mirabegron might be diminished in obese patients.
  
  
  METHODS
  One hundred sixty nine women were prescribed mirabegron, 50mg/day. Subjective and objective parameters were compared prior to and following three months of treatment. The study population was stratified into three groups according to a patients' BMI (A-normal weight, B-overweight, C-obese). We compared the change in parameters before and after treatment within each group. Subsequently the differences between groups were correlated. The same analysis was performed separately in patients who failed anticholinergic therapy (n=85). A paired t-test was used to compare the parameters before and after the procedure within groups, and a two-sample t-test was applied to conduct a comparison between groups. A p value of <0.05 was considered statistically significant.
  
  
  RESULTS
  Significant improvement (p<0.001) within all groups was observed in all parameters, with an exception in the number of severe urgency episodes per 24h (p=0.291) in Group B. We did not observe any statistically significant difference between groups A, B and C. The same trend has been observed in subgroup of patients, who did not respond previous antimuscarinic treatment.
  
  
  CONCLUSIONS
  This study provides evidence in support of previously documented data indicating good efficacy of mirabegron in the treatment of OAB. The data obtained do not confirm our hypothesis that the body weight influences the treatment outcome of mirabegron.
authors.affiliation: Department of Urology, University Hospital, Ostrava, Czech Republic; Department of Surgical Studies, Ostrava University, Ostrava, Czech Republic. Electronic address: jan.krhut@fno.cz.
authors.forename: Jan
authors.initials: J
authors.lastname: Krhut
authors.affiliation: Department of Obstetrics and Gynecology, 1-st Medical Faculty, Charles University and General Faculty Hospital, Prague, Czech Republic.
authors.forename: Alois
authors.initials: A
authors.lastname: Martan
authors.affiliation: Department of Urology, Thomayer's Hospital, Prague, Czech Republic.
authors.forename: Roman
authors.initials: R
authors.lastname: Zachoval
authors.affiliation: Department of Urology, 1-st Medical Faculty, Charles University and General Faculty Hospital, Prague, Czech Republic.
authors.forename: Tomáš
authors.initials: T
authors.lastname: Hanuš
authors.affiliation: Department of Obstetrics and Gynecology, 1-st Medical Faculty, Charles University and General Faculty Hospital, Prague, Czech Republic.
authors.forename: Kamil
authors.initials: K
authors.lastname: Švabík
authors.affiliation: Department of Surgical Studies, Ostrava University, Ostrava, Czech Republic.
authors.forename: Peter
authors.initials: P
authors.lastname: Zvara
mesh_terms: D000083:Acetanilides / Q000627:therapeutic use*; D000368:Aged; D015992:Body Mass Index; D005260:Female; D006801:Humans; D008875:Middle Aged; D012307:Risk Factors; D013844:Thiazoles / Q000627:therapeutic use*; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000503:physiopathology; D064804:Urological Agents / Q000627:therapeutic use*
chemical_list: D000083:Acetanilides; D013844:Thiazoles; D064804:Urological Agents; C520025:mirabegron
keywords: Body mass index; Mirabegron; Overactive bladder; Treatment efficacy